Consequences of the FDA Decision on Aducanumab for Patient Care and Research - 21/11/24
Doi : 10.14283/jpad.2021.43
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Il testo completo di questo articolo è disponibile in PDF.
| Dr. Doody is a Vice President at Genentech, part of the Roche Group, and Franchise Head for Alzheimer’s Disease and Neurodegeneration in late-stage Neuroscience at F. Hoffman LaRoche. She is also Chair of the Alzheimer’s Association Research Roundtable. This editorial represents her personal view and not the position of any group with which she is associated. |
© 2021
THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 8 - N° 4
P. 393-395 - Aprile 2021 Ritorno al numero
Articolo precedente
- How Will Aducanumab Approval Impact AD Research?
- Michael W. Weiner, P.S. Aisen, L.A. Beckett, R.C. Green, W. Jagust, J.C. Morris, O. Okonkwo, R.J. Perrin, R.C. Petersen, M. Rivera Mindt, A.J. Saykin, L.M. Shaw, A.W. Toga, J.Q. Trojanowski, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
- Impact of Aduhelm Approval on Care and Policy
- B. Kallmyer, M. Daven, L. Thornhill, K. Clifford, R. Conant, Maria C. Carrillo
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.